Clinical trials

#Biologics / Biotechnology #Clinical trials #Oncology

The importance of partnership and innovation in oncology

Fostering synergies to accelerate innovation in oncology and make it attractive for partners has been the MATWIN motto for over a decade, writes CEO Lucia Robert, MATWIN who outlines the organisations’s work MATWIN is a French open-innovation platform dedicated to supporting innovation in oncology. For more than ten years, its… Read More

#Cancer Research #Exclusive Content #News

#Clinical trials #Covid-19 #Drug development

ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial

ICON, provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, has announced it provided clinical trial services to the Pfizer and BioNTech investigational COVID-19 vaccine programme. Pfizer and BioNTech announced positive efficacy results from a… Read More

#Covid-19 #News

#Clinical trials #Immunology / Virology & Vaccines #Therapeutics

Peanut allergy biomarker study may lead to novel peanut vaccine candidate

Allergy Therapeutics, the specialty pharmaceutical company specialising in allergy vaccines, has announced that an ex-vivo biomarker study of blood samples from peanut allergy patients has begun at Imperial College London. The study aims to evaluate the group’s novel virus like particle (VLP) based peanut allergy vaccine candidate, to confirm its… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Clinical trials

Healthtech specialist Novadiscovery teams up with with Janssen France

Novadiscovery, a healthtech company offering the clinical trial simulation platform, Jinkō, to predict drug efficacy and optimize clinical trial development, has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with forward-looking industry leaders to… Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

UC Davis Health joins Novavax in testing new COVID-19 vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health. The health system is expected to launch a stage III clinical trial with the National Institutes of Health (NIH) and… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Vaccines

The ethics of human challenge trials

Rutgers Research Professor, Daniel Hausman, examines the ethical questions around human challenge trials for COVID-19 vaccines The first human challenge trial to test COVID-19 treatments and vaccines is set to begin in January in the United Kingdom. These trials, in which healthy volunteers are infected with the virus after being… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Biotechnology #Clinical trials

Oxeia Biopharmaceuticals announces Phase II trial for concussion treatment

Oxeia Biopharmaceuticals is a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury. It has announced the initiation of a Phase II clinical trial of OXE103 for treating concussion. The Phase II clinical study is being conducted by Dr. Michael Rippee,… Read More

#News

#Clinical trials #Drug candidates #Drug targets #Life sciences #Therapeutics

One Nucleus announces life science award shortlist

One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies with exciting developments. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced. Companies and research organisations were nominated for their most important updates from the last… Read More

#News

#Clinical trials #Covid-19 #Therapeutics

The 100 year-old therapy that may prevent COVID-19 after exposure to the virus

Most media and public attention during the pandemic has focused upon efforts to develop an effective vaccine to prevent COVID-19, which is caused by the novel coronavirus SARS-CoV-2. Some attention has been paid to investigational therapeutics for treating infected patients, such as the antiviral drug remdesivir or the corticosteroid dexamethasone,… Read More

#Covid-19 #Editor's Choice #News

#Business #Clinical trials #Therapeutics

Drug launches to drive NASH growth across major markets, says research

Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is anticipated that these products can demand higher prices than the current off-label therapies, considering no therapy has been approved for the indication, and drive strong… Read More

#News #Trends & Analysis

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford COVID-19 vaccine 70% effective

The University of Oxford, in collaboration with AstraZeneca, has announced interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection. Following the trial reaching the target for interim analysis, the independent Data… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Immunology / Virology & Vaccines

New study indicates Ebola vaccine safe, and produces robust immune response

Scientists from the University of Oxford, working as part of the EBOVAC2 EBL2001 study group, have announced the results of a Phase II trial of a replication-deficient adenovirus vaccine aimed at providing protection against the lethal Ebola virus. Writing in the journal Lancet: Infectious Diseases, they conclude that the two-dose… Read More

#News